NasdaqGM - Delayed Quote • USD
Vericel Corporation (VCEL)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 4:01 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 5 | 6 | 6 |
| Avg. Estimate | -0.11 | -0.07 | 0.08 | 0.49 |
| Low Estimate | -0.17 | -0.13 | 0 | 0.27 |
| High Estimate | -0.05 | -0.02 | 0.16 | 0.61 |
| Year Ago EPS | -0.16 | -0.11 | -0.07 | 0.08 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 49.07M | 54.33M | 239.24M | 299.15M |
| Low Estimate | 48.4M | 51.9M | 237.25M | 284.55M |
| High Estimate | 50.41M | 59.9M | 240.54M | 318.03M |
| Year Ago Sales | 37.87M | -- | 197.52M | 239.24M |
| Sales Growth (year/est) | 29.60% | -- | 21.10% | 25.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.15 | -0.15 | -0.12 | 0.17 |
| EPS Actual | -0.16 | -0.11 | -0.08 | 0.26 |
| Difference | -0.01 | 0.04 | 0.04 | 0.09 |
| Surprise % | -6.70% | 26.70% | 33.30% | 52.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.11 | -0.07 | 0.08 | 0.49 |
| 7 Days Ago | -0.11 | -0.07 | 0.08 | 0.49 |
| 30 Days Ago | -0.11 | -0.07 | 0.08 | 0.49 |
| 60 Days Ago | -0.09 | -0.04 | 0.12 | 0.54 |
| 90 Days Ago | -0.1 | -0.04 | 0.09 | 0.5 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VCEL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 31.20% | -- | -- | 0.80% |
| Next Qtr. | 36.40% | -- | -- | 9.60% |
| Current Year | 214.30% | -- | -- | 4.50% |
| Next Year | 512.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Truist Securities: Buy to Buy | 3/26/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/1/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Upgrade | Truist Securities: Hold to Buy | 1/25/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/16/2024 |
| Maintains | Truist Securities: Hold to Hold | 11/9/2023 |
Related Tickers
MDWD MediWound Ltd.
16.99
-2.58%
PTGX Protagonist Therapeutics, Inc.
25.22
-1.37%
LSTA Lisata Therapeutics, Inc.
2.8500
+4.01%
VRCA Verrica Pharmaceuticals Inc.
6.90
-2.27%
KNSA Kiniksa Pharmaceuticals, Ltd.
16.88
-0.41%
VSTM Verastem, Inc.
10.23
-5.63%
SPRY ARS Pharmaceuticals, Inc.
8.44
-6.84%
INSM Insmed Incorporated
24.80
-5.27%
PEPG PepGen Inc.
11.85
+3.00%
SYRE Spyre Therapeutics, Inc.
35.58
+3.70%